Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanghuangyin
- Development stage
- Phase 4
- Lead developer
- Zhejiang Province Cancer Hospital
- Administration
- Oral
01
Overview
Compound Sanghuangyin is a Traditional Chinese Medicine (TCM) formulation primarily derived from the medicinal fungus *Phellinus linteus* (Sanghuang). It is developed by Zhejiang Cancer Hospital as a hepatoprotective agent for patients with primary liver cancer (hepatocellular carcinoma). The drug is specifically investigated for its ability to mitigate acute liver injury following interventional procedures such as Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC). Administered orally, it is intended to complement standard hepatoprotective therapies by leveraging the anti-inflammatory and antioxidant properties associated with *Phellinus linteus* extracts.
- Other names
- SanghuangyinCompound SanghuangyinFufang Sanghuangyin
Beyond the preview
Go deeper on Sanghuangyin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sanghuangyin.